Celsion's ThermoDox for liver cancer shows positive overall survival data Celsion updated results from its retrospective analysis of the company's 701-patient HEAT Study of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation in primary liver cancer. As of June 30, the latest quarterly Overall Survival analysis demonstrated that in 41% of the study patients, the combination of ThermoDox and optimized RFA provided a 57% improvement in OS compared to optimized RFA alone. Data from the latest HEAT Study post-hoc analysis continued to strongly suggest that ThermoDox may significantly improve OS compared to a RFA control in patients whose lesions undergo RFA treatment for 45 minutes or more.
News For CLSN From The Last 14 Days
Check below for free stories on CLSN the last two weeks.